Patent · US Active

Tau immunotherapy

US11643457B2 · kind B2 · utility

0Cited by

60References

12Claims

0Family size

Assignee

Prothena Biosciences Limited · IE

Inventors

Peter A. Seubert · South San Francisco, US
Philip James Dolan, III · Foster City, US
Yue Liu · Foster City, US
Robin Barbour · Newark, US

Key dates

Filing date	Oct 29, 2019
Grant date	May 9, 2023
Priority date	—
Expiry date	Oct 29, 2039

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/2821
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.